Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2002 | P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; KING-JEN CHANG | International Journal of Cancer | 66 | 57 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2015 | Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma | CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu | Radiotherapy and Oncology | 9 | 8 | |
2006 | A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus | Pei Y.Y.; SUNG-HSIN KUO ; KUN-HUEI YEH ; Chuang S.-E.; CHIH-HUNG HSU ; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG | Journal of Biological Chemistry | 43 | 39 | |
2022 | Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia | Cao, Y; Qin, S; Luo, S; Li, Z; Cheng, Y; Fan, Y; Sun, Y; Yin, X; Yuan, X; Li, W; Liu, T; CHIH-HUNG HSU ; Lin, X; Kim, S-B; Kojima, T; Zhang, J; Lee, S-H; Bai, Y; Muro, K; Doi, T; Bai, C; Gu, K; Pan, H-M; Bai, L; Yang, J-W; Cui, Y; Lu, W; Chen, J | ESMO open | 24 | 18 | |
2000 | Persistent severe hypocapnia and alkalemia in a 40-year-old woman | CHIA-HSUIN CHANG ; PING-HUNG KUO ; CHIH-HUNG HSU ; PAN-CHYR YANG | Chest | 8 | 6 | |
2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 24 | 25 | |
2001 | Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | ANN-LII CHENG ; CHIH-HUNG HSU ; Lin J.-K.; Hsu M.-M.; YUNN-FANG HO ; She T.-S.; JENG-YUH KO ; Lin J.-T.; BOR-RU LIN ; MING-SHIANG WU ; Yu H.-S.; SHIOU-HWA JEE ; Chen G.-S.; Chen T.-M.; CHI-AN CHEN ; Lai M.-K.; YEONG-SHIAU PU ; MIN-HSIUNG PAN ; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH | Anticancer Research | 1925 | 1695 | |
2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 | |
2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |
2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
2019 | Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma | Ta-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 8 | 6 | |
1997 | A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers | KUN-HUEI YEH ; ANN-LII CHENG ; Lin M.-T.; RUEY-LONG HONG ; CHIH-HUNG HSU ; Lin J.-F.; KING-JEN CHANG ; PO-HUANG LEE ; YAO-CHANG CHEN | Anticancer Research | 32 | 27 | |
2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |
2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |